Exelixis, Inc. (NASDAQ:EXEL) Belonging to the Medical sector which surged 4.15% and closed its last trading session at $12.79.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/8/2016. Currently, the stock has a 1 Year Price Target of $12.67.
The consensus recommendation, according to Zacks Investment research, is 1.4. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.4 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.4 and 1.4 respectively.
Exelixis, Inc. on 6/30/2016 reported its EPS as $-0.16 with the analysts projecting the EPS of the stock as $-0.27. The company beat the analyst EPS Estimate with the difference of $0.11. This shows a surprise factor of 40.7%.
Many analysts have provided their estimated foresights on Exelixis, Inc. Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.13. Whereas they predicted High and Low Earnings Estimate as $-0.07 and $-0.2 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.22.
Analysts are also projecting an Average Revenue Estimate for Exelixis, Inc. as $43.84 Million in the Current Quarter. This estimate is provided by 5 analysts. The High Revenue estimate is predicted as 58.62 Million, while the Low Revenue Estimate prediction stands at 32 Million. The company’s last year sales total was 9.85 Million.
For the Current Quarter, the growth estimate for Exelixis, Inc. is 40.9%, while for the Next Quarter the stock growth estimate is 57.9%. In the past 5 years, the stock showed growth of 0% per annum. While for the next 5 years, the growth estimate is -24.1%.
The Company got Upgrade by Stifel on 4-Apr-16 from Hold to Buy.
Insider Trades for Exelixis, Inc. show that the latest trade was made on 25 Sep 2016 where Morrissey (Michael M), the Chief Executive Officer completed a transaction type “Buy” in which 60000 shares were traded at a price of $0.
1 Insider Sales transactions were made totaling 300876 shares traded.
3 analysts projected Price Targets for Exelixis, Inc. The analysts believe that the company stock price could grow as high as $15. The Low Price target projection by analysts is $8 and the Mean Price Target is $12.67.
Exelixis, Inc. (NASDAQ:EXEL) has the market capitalization of $2.83 Billion. The company rocked its 52-Week High of $15.58 on Sep 28, 2016 and touched its 52-Week Low of $3.55 on Mar 17, 2016. The stock has Return on Assets (ROA) of -45.5 percent. Return on Equity (ROE) stands at 145.6% and Return on Investment (ROI) of -43.8 percent.
The stock is currently showing YTD performance of 126.77 Percent. The company has Beta Value of 1.94 and ATR value of 0.77. The Weekly and Monthly Volatility stands at 10.56% and 5.41%.
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.